🇺🇸 Paclitaxel (Taxol) in United States

480 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Nausea — 58 reports (12.08%)
  2. Neutrophil Count Decreased — 58 reports (12.08%)
  3. Vomiting — 57 reports (11.88%)
  4. Dyspnoea — 52 reports (10.83%)
  5. Dehydration — 51 reports (10.62%)
  6. Neutropenia — 50 reports (10.42%)
  7. Diarrhoea — 47 reports (9.79%)
  8. Asthenia — 36 reports (7.5%)
  9. Hypotension — 36 reports (7.5%)
  10. Pyrexia — 35 reports (7.29%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Paclitaxel (Taxol) approved in United States?

Paclitaxel (Taxol) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Paclitaxel (Taxol) in United States?

M.D. Anderson Cancer Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.